Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00350948 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer
A Phase 3 study, sponsored by Telik.
- Terminated
- Registry status
- Phase 3
- Development phase
- 244
- Enrollment target
NCT00350948 is a Phase 3 study that was terminated before completion, run by Telik. The registered enrollment target is 244 participants.
The verdict
NCT00350948, a Phase 3 study, was terminated before completion, sponsored by Telik.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 244 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine if Telcyta® given in combination with liposomal doxorubicin is more effective than liposomal doxorubicin alone in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer or primary peritoneal cancer that is refractory or resistant to platinum chemotherapy.
Interventions
- DRUG Liposomal Doxorubicin
- DRUG Telcyta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00350948
The ClinicalTrials.gov registry entry for NCT00350948 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 244 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Telik, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Liposomal Doxorubicin is the first listed.
NCT00350948 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00350948 about?
NCT00350948 is a clinical study titled "Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer". The purpose of this research study is to determine if Telcyta® given in combination with liposomal doxorubicin is more effective than liposomal doxorubicin alone in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer or primary peritoneal cancer that is refractory or r...
What is the current status of trial NCT00350948?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 244 participants. The study started on 2006-05. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00350948?
The interventions under investigation include: Liposomal Doxorubicin (DRUG), Telcyta (DRUG).
Who is sponsoring clinical trial NCT00350948?
This trial is sponsored by Telik, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.